Immunologic Research

, Volume 42, Issue 1–3, pp 233–245 | Cite as

Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors

  • Laurence M. Wood
  • Patrick D. Guirnalda
  • Matthew M. Seavey
  • Yvonne Paterson
Article

Abstract

Our laboratory is interested in how immunogenicity may be modulated in vivo in order to better design more effective immunotherapeutics against cancer. Our main approach is to use a facultative intracellular bacterium, Listeria monocytogenes, which has the unusual ability to live and grow in the cytoplasm of the cell and is thus an excellent vector for targeting passenger antigens to the major histocompatibility complex (MHC) class I pathway of antigen processing with the generation of authentic CTL epitopes. We have used this approach to target tumor antigens expressed on breast, melanoma and cervical cancer. We are also exploring the role of Listerial virulence factors in potentiating adaptive immune responses by activating innate immunity. Specifically, we are using these proteins as adjuvants for B cell lymphomas.

Keywords

Listeriamonocytogenes HPV Her-2/neu Tumor immunotherapy Tumor vasculature Vaccines Antigen processing Cell-mediated immunity 

Notes

Acknowledgments

We thank all the current and past members of the Paterson laboratory for their contributions to these studies and, in particular Dr. Zhen-Kun Pan, for her unswerving support and industry for the past 18 years. Yvonne Paterson wishes to disclose that she has a financial interest in Advaxis, Inc., a vaccine and therapeutic company that has licensed or has an option to license all patents from the University of Pennsylvania that concern the use of Listeria or listerial products as vaccines.

References

  1. 1.
    Sabin A. Presidential Address to the Infectious Disease Society of America. 1983.Google Scholar
  2. 2.
    Paterson Y. Rational approaches to immune regulation. Immunol Res. 2003;27:451–62. (Cancro M, Monroe J, editors).Google Scholar
  3. 3.
    Paterson Y. The relationship between bacterial life-styles and the immune responsiveness to bacterially delivered antigens. In: Paterson Y, editor. Intracellular bacteria as live recombinant vaccine vectors Immunology cell biology and genetics. New York, NY: Wiley; 1999. p. 1–24.Google Scholar
  4. 4.
    Tilney LG, Portnoy DA. Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J Cell Biol. 1989;109:1597–1608.PubMedCrossRefGoogle Scholar
  5. 5.
    Portnoy DA, Schreiber RD, Connelly P, Tilney LG. Gamma interferon limits access of Listeria monocytogenes to the macrophage cytoplasm. J Exp Med. 1989;170:2141–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Kaufmann SHE. Immunity to intracellular bacteria. Annu Rev Immunol. 1993;11:129–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Czuprynski CJ, Brown JF. Dual regulation of anti-bacterial resistance and inflammatory neutrophil and macrophage accumulation by L3T4+ and Lyt 2+ Listeria immune T cells. Immunology. 1987;60:287–93.PubMedGoogle Scholar
  8. 8.
    Mielke ME, Ehlers S, Hahn H. T-cell subsets in delayed-type hypersensitivity, protection and granuloma formation in primary and secondary Listeria infection in mice: Superior role of Lyt-2+ cells in acquired immunity. Infect Immun. 1988;56:1920–5.PubMedGoogle Scholar
  9. 9.
    Brunt LM, Portnoy DA, Unanue ER. Presentation of Listeria monocytogenes to CD8+ T cells requires secretion of hemolysin and intracellular bacterial growth. J Immunol. 1990;145:3540–6.PubMedGoogle Scholar
  10. 10.
    Berche P, Gaillard J, Sansonetti PJ. Intracellular growth of Listeria monocytogenes as a prerequisite for in vivo induction of T cell-mediated immunity. J Immunol. 1987;138:2266–71.PubMedGoogle Scholar
  11. 11.
    Weiskirch L, Paterson Y. The use of Listeria monocytogenes recombinants as vaccine vectors in infectious and neoplastic disease. In: Paterson Y, editor. Chapter 7 in Intracellular bacteria as live recombinant vaccine vectors: Immunology, cell biology and genetics. New York, NY: Wiley; 1999. p. 223–59.Google Scholar
  12. 12.
    Vijh S, Pamer EG. The cell biology and immune response to Listeria monocytogenes, an intracellular pathogen. In: Paterson Y, editor. Chapter 3 in Intracellular bacteria as live recombinant vaccine vectors: Immunology, cell biology and genetics. New York, NY: Wiley; 1999.Google Scholar
  13. 13.
    Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Jones LA, Salgaller ML. Immunologic approaches to antigen discovery for cancer vaccines. Expert Opin Investig Drugs. 2000;9:481–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Pardoll DM. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA. 1999;96:5340–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Pan Z-K, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour challenge and causes regression of established tumours. Nat Med. 1995;1:471–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Pan Z-K, Ikonomidis G, Pardoll D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res. 1995;55:4776–9.PubMedGoogle Scholar
  18. 18.
    Pan Z-K, Weiskirch LM, Paterson Y. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res. 1999;59:5264–9.PubMedGoogle Scholar
  19. 19.
    Weiskirch LM, Pan Z-K, Paterson Y. The tumor recall response of anti-tumor immunity primed by a live, recombinant L. monocytogenes vaccine is comprised of multiple effector mechanisms. Clin Immunol. 2001;98:346–57.PubMedCrossRefGoogle Scholar
  20. 20.
    Ikonomidis G, Paterson Y, Kos F, Portnoy D. Delivery of a viral antigen to the class I processing and presentation pathway by L. monocytogenes. J Exp Med. 1994;180:2209–18.PubMedCrossRefGoogle Scholar
  21. 21.
    Jaffee EM, Pardoll DM. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods. 1997;12:143–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Antonia SJ. B7-1 gene-modified tumor cell vaccines. Curr Opin Mol Ther. 1999;1:50–6.PubMedGoogle Scholar
  23. 23.
    Dominiecki ME, Beatty GL, Pan Z-K, Neeson P, Paterson Y. Tumor sensitivity to IFNγ is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol Immunother. 2005;54:477–88.PubMedCrossRefGoogle Scholar
  24. 24.
    Tindle RW. Human papilloma virus vaccines for cervical cancer. Curr Opin Immunol. 1996;8:643–50.PubMedCrossRefGoogle Scholar
  25. 25.
    Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21–6.PubMedGoogle Scholar
  26. 26.
    Gunn GR, Zubair A, Peters CH, Pan Z-K, Wu T-C, Paterson Y. Two L. monocytogenes vaccine vectors that express different molecular forms of HPV-16 E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167:6471–9.PubMedGoogle Scholar
  27. 27.
    Gunn GR, Peters C, Paterson Y. Listeriolysin––a useful cytolysin. Trends in Microbiol. 2001;9:161–2.CrossRefGoogle Scholar
  28. 28.
    Sewell DA, Shahabi V, Gunn GR III, Pan Z-K, Dominiecki ME, Paterson Y. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor associated antigen human papillomavirus-16 E7. Cancer Res. 2004;64:8821–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Lamikanra A, Pan Z-K, Isaacs S, Wu T-C, Paterson Y. The ability to induce the regression of established HPV-16 immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8+ T cell responses that home to the tumor site. J Virol. 2001;75:9654–64.PubMedCrossRefGoogle Scholar
  30. 30.
    Sewell DA, Douven D, Pan Z-K, Rodriguez A, Paterson Y. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg. 2004;130:92–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Peng X, Treml J, Paterson Y. Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy. Cancer Immunol Immunother. 2007;56:797–806.PubMedCrossRefGoogle Scholar
  32. 32.
    Noor S, Goldfine H, Tucker DE, Suram S, Lenz LL, Akira S, et al. Activation of cytosolic phospholipase A2alpha in resident peritoneal macrophages by Listeria monocytogenes involves listeriolysin O and TLR2. J Biol Chem. 2008;283:4744–55.PubMedCrossRefGoogle Scholar
  33. 33.
    Nishibori T, Xiong H, Kawamura I, Arakawa M, Mitsuyama M. Induction of cytokine gene expression by listeriolysin O and roles of macrophages and NK cells. Infect Immun. 1996;64:3188–95.PubMedGoogle Scholar
  34. 34.
    Kohda C, Kawamura I, Baba H, et al. Dissociated linkage of cytokine-inducing activity and cytotoxicity to different domains of listeriolysin O from Listeria monocytogenes. Infect Immun. 2002;70:1334–41.PubMedCrossRefGoogle Scholar
  35. 35.
    Neeson P, Pan ZK, Paterson Y. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma. Cancer Immunol Immunother. 2008;57:493–505.PubMedCrossRefGoogle Scholar
  36. 36.
    Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, et al. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood. 1994;83:3279–88.PubMedGoogle Scholar
  37. 37.
    Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol. 1977;7:413–17.PubMedCrossRefGoogle Scholar
  38. 38.
    Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol. 1987;138:1289–96.PubMedGoogle Scholar
  39. 39.
    Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol. 2001;167:1137–40.PubMedGoogle Scholar
  40. 40.
    Anthony PA, Restifo NP. Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother. 2002;25:202–6.CrossRefGoogle Scholar
  41. 41.
    Hussain SF, Paterson Y. CD4+ CD 25+ Regulatory T cells that secrete TGFβ and IL-10 are preferentially induced by a vaccine vector. J Immunother. 2004;27(5):339–46.PubMedCrossRefGoogle Scholar
  42. 42.
    Nitcheu-Tefit J, Dai M-S, Critchley-Thorne RJ, Ramirez-Jimenez F, Xu M, Conchon S, et al. Listeriolysin O expressed in a bacterial vaccine suppresses CD4+ CD25 high regulatory T cell function in vivo. J Immunol. 2007;179:1532–41.PubMedGoogle Scholar
  43. 43.
    Souders NC, Sewell DA, Pan Z-K, Hussain SF, Rodriguez A, Wallecha A, et al. Listeria based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun. 2007;7:1–12.Google Scholar
  44. 44.
    Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, et al. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer. 2002;9:33–44.PubMedCrossRefGoogle Scholar
  45. 45.
    Ercolini AM, et al. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol. 2003;170:4273–80.PubMedGoogle Scholar
  46. 46.
    Muller WJ. Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer. Cancer Metastasis Rev. 1991;10:217–27.PubMedCrossRefGoogle Scholar
  47. 47.
    Guy CT, et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA. 1992;89:10578–82.PubMedCrossRefGoogle Scholar
  48. 48.
    Singh R. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol. 2005;175:3663–73.PubMedGoogle Scholar
  49. 49.
    Singh R, Paterson Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res. 2007;67:1887–92.PubMedCrossRefGoogle Scholar
  50. 50.
    Singh R, Paterson Y. Vaccination strategy determines the emergence and dominance of CD8 + T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. Cancer Res. 2006;66:7748–57.PubMedCrossRefGoogle Scholar
  51. 51.
    Singh R, Paterson Y. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother. 2007;56:927–38.PubMedCrossRefGoogle Scholar
  52. 52.
    Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol. 2004;24:267–96.PubMedCrossRefGoogle Scholar
  53. 53.
    Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15:102–11.PubMedCrossRefGoogle Scholar
  54. 54.
    Von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell Res. 2006;312(5):623–9.CrossRefGoogle Scholar
  55. 55.
    Maciag P, Seavey M, Pan Z, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res. 2008;68:8066–75.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Laurence M. Wood
    • 1
  • Patrick D. Guirnalda
    • 1
  • Matthew M. Seavey
    • 1
  • Yvonne Paterson
    • 1
  1. 1.Department of MicrobiologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations